455 related articles for article (PubMed ID: 32416756)
1. [Cutaneous Toxicity of Immune Checkpoint Inhibitors: A Narrative Review].
Gomes N; Sibaud V; Azevedo F; Magina S
Acta Med Port; 2020 May; 33(5):335-343. PubMed ID: 32416756
[TBL] [Abstract][Full Text] [Related]
2. Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy.
Sibaud V
Am J Clin Dermatol; 2018 Jun; 19(3):345-361. PubMed ID: 29256113
[TBL] [Abstract][Full Text] [Related]
3. Immune checkpoint inhibitor-related dermatologic adverse events.
Geisler AN; Phillips GS; Barrios DM; Wu J; Leung DYM; Moy AP; Kern JA; Lacouture ME
J Am Acad Dermatol; 2020 Nov; 83(5):1255-1268. PubMed ID: 32454097
[TBL] [Abstract][Full Text] [Related]
4. Cutaneous Immune-Related Adverse Events (irAEs) to Immune Checkpoint Inhibitors: A Dermatology Perspective on Management [Formula: see text].
Muntyanu A; Netchiporouk E; Gerstein W; Gniadecki R; Litvinov IV
J Cutan Med Surg; 2021; 25(1):59-76. PubMed ID: 32746624
[TBL] [Abstract][Full Text] [Related]
5. Adverse cutaneous toxicities by PD-1/PD-L1 immune checkpoint inhibitors: pathogenesis, treatment, and surveillance.
Bhardwaj M; Chiu MN; Pilkhwal Sah S
Cutan Ocul Toxicol; 2022 Mar; 41(1):73-90. PubMed ID: 35107396
[TBL] [Abstract][Full Text] [Related]
6. Dermatologic toxicities to immune checkpoint inhibitor therapy: A review of histopathologic features.
Ellis SR; Vierra AT; Millsop JW; Lacouture ME; Kiuru M
J Am Acad Dermatol; 2020 Oct; 83(4):1130-1143. PubMed ID: 32360716
[TBL] [Abstract][Full Text] [Related]
7. Cutaneous immune-related adverse events to checkpoint inhibitors.
Malviya N; Tattersall IW; Leventhal J; Alloo A
Clin Dermatol; 2020; 38(6):660-678. PubMed ID: 33341200
[TBL] [Abstract][Full Text] [Related]
8. Cutaneous adverse effects of the immune checkpoint inhibitors.
Collins LK; Chapman MS; Carter JB; Samie FH
Curr Probl Cancer; 2017; 41(2):125-128. PubMed ID: 28190531
[TBL] [Abstract][Full Text] [Related]
9. Cutaneous Adverse Events of Immune Checkpoint Inhibitors: A Summarized Overview.
Plachouri KM; Vryzaki E; Georgiou S
Curr Drug Saf; 2019; 14(1):14-20. PubMed ID: 30058498
[TBL] [Abstract][Full Text] [Related]
10. Cutaneous manifestations associated with immune checkpoint inhibitors.
Watanabe T; Yamaguchi Y
Front Immunol; 2023; 14():1071983. PubMed ID: 36891313
[TBL] [Abstract][Full Text] [Related]
11. Cutaneous Hypersensitivity Reactions to Immune Checkpoint Inhibitors.
Storgard R; Markova A
J Allergy Clin Immunol Pract; 2024 May; 12(5):1132-1136. PubMed ID: 38548170
[TBL] [Abstract][Full Text] [Related]
12. Cutaneous Adverse Events Associated with Immune Checkpoint Inhibitors: A Review Article.
Chen CH; Yu HS; Yu S
Curr Oncol; 2022 Apr; 29(4):2871-2886. PubMed ID: 35448208
[TBL] [Abstract][Full Text] [Related]
13. Inflammatory eruptions associated with immune checkpoint inhibitor therapy: A single-institution retrospective analysis with stratification of reactions by toxicity and implications for management.
Coleman E; Ko C; Dai F; Tomayko MM; Kluger H; Leventhal JS
J Am Acad Dermatol; 2019 Apr; 80(4):990-997. PubMed ID: 30399387
[TBL] [Abstract][Full Text] [Related]
14. Cutaneous adverse reactions to anti-PD-1 treatment-A systematic review.
Simonsen AB; Kaae J; Ellebaek E; Svane IM; Zachariae C
J Am Acad Dermatol; 2020 Nov; 83(5):1415-1424. PubMed ID: 32320766
[TBL] [Abstract][Full Text] [Related]
15. How to recognize and manage skin toxicities associated with immune checkpoint inhibitors: a practical approach.
Kawsar A; Hussain K; Muinonen-Martin AJ; Fearfield L
Br J Dermatol; 2023 Oct; 189(Suppl 1):i3-i10. PubMed ID: 37903072
[TBL] [Abstract][Full Text] [Related]
16. [Dermatologic toxicities of immune checkpoint inhibitors].
Sibaud V; Boulinguez S; Pagès C; Riffaud L; Lamant L; Chira C; Boyrie S; Vigarios E; Tournier E; Meyer N
Ann Dermatol Venereol; 2018 May; 145(5):313-330. PubMed ID: 29678394
[TBL] [Abstract][Full Text] [Related]
17. Characteristics, Management, and Prognostic Implications of Adverse Effects of Immune Checkpoint Inhibitors: A Systematic Review.
Juan-Carpena G; Palazón-Cabanes JC; Blanes-Martínez M
Actas Dermosifiliogr; 2022 Apr; 113(4):376-387. PubMed ID: 35623728
[TBL] [Abstract][Full Text] [Related]
18. Cutaneous Eruptions in Patients Receiving Immune Checkpoint Blockade: Clinicopathologic Analysis of the Nonlichenoid Histologic Pattern.
Kaunitz GJ; Loss M; Rizvi H; Ravi S; Cuda JD; Bleich KB; Esandrio J; Sander I; Le DT; Diaz LA; Brahmer JR; Drake CG; Hollmann TJ; Lacouture ME; Hellmann MD; Lipson EJ; Taube JM
Am J Surg Pathol; 2017 Oct; 41(10):1381-1389. PubMed ID: 28817405
[TBL] [Abstract][Full Text] [Related]
19. Epidemiology and risk factors for the development of cutaneous toxicities in patients treated with immune-checkpoint inhibitors: A United States population-level analysis.
Wongvibulsin S; Pahalyants V; Kalinich M; Murphy W; Yu KH; Wang F; Chen ST; Reynolds K; Kwatra SG; Semenov YR
J Am Acad Dermatol; 2022 Mar; 86(3):563-572. PubMed ID: 33819538
[TBL] [Abstract][Full Text] [Related]
20. Immune-mediated adverse effects of immune-checkpoint inhibitors and their management in cancer.
Jin KT; Wang SB; Ying XJ; Lan HR; Lv JQ; Zhang LH; Motallebnezhad M; Mou XZ
Immunol Lett; 2020 May; 221():61-71. PubMed ID: 32097671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]